|
|
Post by mnkdfann on Jul 7, 2019 15:56:38 GMT -5
I do think you are correct though and it is not a threat to Afrezza in the US and Europe, but it probably forecloses the Chinese market and likely a lot of Asia as well. Being in a trade war with China isn't going to help with IP enforcement either. The more interesting question is if they will start using FDKP for other drugs. That might actually help because right now FDKP inhaled drugs are a bit of a backwater and China could definitely provide credibility. Why not a threat in Europe? Statistics I found online suggest that China exports about 50% more to Europe than the U.S. does. So Europe seems quite comfortably importing Chinese products. |
|
|
|
Post by mnkdfann on Jul 7, 2019 15:52:22 GMT -5
|
|
|
|
Post by mnkdfann on Jul 7, 2019 14:39:38 GMT -5
Says the paper: "Although the inhaled insulin powder Afrezza®, which has been marketed, can significantly reduce the incidence of hypoglycemia and relieve the pain of patients, the sales volume and the market feedback of Afrezza® is unsatisfactory as well. The reason for the poor sales of Afrezza® may be that people are still skeptical about the safety of insulin DPIs, and the price of the inhaler and its associated inhalation device is higher than that of insulin injection (Fantasia, 2015 Fantasia HC. (2015). Inhaled insulin – a new delivery for an old drug. Nurs Womens Health 19:67–70.). Compared with Afrezza®, this paper aims to optimize the preparation process of INS@FDKP-MPs by adopting a simpler and more convenient synthesis method to reduce the production cost, and by evaluating the properties of INS@FDKP-MPs, it is intended to construct an inhalable insulin preparation that is qualified in particle size, drug loading, hypoglycemic effect, and safety." China don't want Afrezza. They say they are working on something better. Thumbs up for finding the language that concerns me, not because I like the notion.  Unless Mannkind is assisting behind the scenes and realizes changing the method for preparation in the U.S. would be daunting and plan on moving forward in China with a different process. I can only imagine the IP mote that is around Afrezza, but I also don't know that any of it would ever slow China down. Anything is possible, but Occam's razor suggests it is just what the article says it is. China looking for a new improved better replacement for Afrezza. (And see funding note below.) If it was Mannkind behind the scenes, why would the paper be bad-mouthing Afrezza by commenting on its relative high cost, poor sales, people worried about its safety, etc? So I'm surprised there are 'longs' over at StockTwits giving this paper a thumbs up, but nothing surprises me much any more. BTW, in case anyone missed details about the paper's funding: "This work was supported by the Ministry of Science and Technology of China (No. 2017ZX09101001-005-003), the National Natural Science Foundation of China (No. 81501579) and (No. 81673364), the Natural Science Foundation of Jiangsu Province (No. BK20150702), the Science and Technology Development Fund of Nanjing Medical University (2016NJMU105), the Priority Academic Program Development of Jiangsu Higher Education Institutions and the Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX17_0674)." |
|
|
|
Post by mnkdfann on Jul 7, 2019 11:52:54 GMT -5
Says the paper:
"Although the inhaled insulin powder Afrezza®, which has been marketed, can significantly reduce the incidence of hypoglycemia and relieve the pain of patients, the sales volume and the market feedback of Afrezza® is unsatisfactory as well. The reason for the poor sales of Afrezza® may be that people are still skeptical about the safety of insulin DPIs, and the price of the inhaler and its associated inhalation device is higher than that of insulin injection (Fantasia, 2015 Fantasia HC. (2015). Inhaled insulin – a new delivery for an old drug. Nurs Womens Health 19:67–70.). Compared with Afrezza®, this paper aims to optimize the preparation process of INS@FDKP-MPs by adopting a simpler and more convenient synthesis method to reduce the production cost, and by evaluating the properties of INS@FDKP-MPs, it is intended to construct an inhalable insulin preparation that is qualified in particle size, drug loading, hypoglycemic effect, and safety."
China don't want Afrezza. They say they are working on something better.
|
|
|
|
Post by mnkdfann on Jul 6, 2019 18:46:19 GMT -5
And I still say ... the quarterly CC is coming to a theater near you. But, that's mytakeonit ? (serious question, I know it’s happened but it seems long long ago) I have no such memory. Though I can imagine some people on this forum saying at the time that some news was game changing. |
|
|
|
Post by mnkdfann on Jul 6, 2019 11:23:58 GMT -5
Another earthquake near LA today. Anyone think to check on Westlake HQ? With Mannkind's luck ...
|
|
|
|
Post by mnkdfann on Jul 6, 2019 9:04:11 GMT -5
You shouldn't expect them to do charity work. VDEX asked for a deal MNKD said no, so now VDEX is trying to pressure stock holders into pushing for a hand out. Yes a hand out. They are offering no money in the deal. If they know they can sell Afrezza why not use the approach above, or why dont they hit up kickstarter or Gofund me, or sell shares, which might actually work(oh wait they are private and dont want to sell off a piece of their companies). What is so precious about non exclusive distribution rights they are proposing unless there is a poison pill in there somewhere for MNKD? What irony that the HFM site includes a statement: "Our only question is, why would someone that holds stock in a company be an advocate of an action that potentially harms their investment?" |
|
|
|
Post by mnkdfann on Jul 5, 2019 15:37:37 GMT -5
We hit our low while losing a CEO and we rallied on gaining a new one.. lets talk about something else.. Thanks Age Rallied? We’re at 1.10 two years later, amazing performance... Oh, the SP performance sucks, no two ways about it. |
|
|
|
Post by mnkdfann on Jul 5, 2019 15:34:25 GMT -5
And if you look at the historical prices, you'll see that it was about 70 cents when MC was presumably approached and agreed to be CEO. After which the price mysteriously started rising significantly over a couple of weeks (my guess it had something to do with some knowing or strongly suspecting that a new CEO was being installed). So, yes, it wasn't 70 cents when he publicly took over but it very possibly and likely was when he agreed to do so. How is it you know the date MC was “approached” ? As you claim I made no such claim. I'm just saying it is logical (obvious) that MC must have privately accepted to become CEO some time before it was publicly announced. I assume discussions went on for at least a few weeks beforehand (consistent with what Vdex said about MC wanting and trying to become CEO), and some people must have known Matt was on the way out. The shares were around 0.70 just a short while before the new CEO was publicly announced. I think it makes sense and is perfectly understandable if MC was thinking of the share price the day he accepted the role, and not the day it was publicly announced. IMO you might fairly accuse him of misspeaking (but see below). But if you use what MC said as some example of intentional lying, I think it is possible that you may be stretching it. Furthernore, what you originally wrote was: "MC also claimed the share price was .70 cent range when he took over as CEO." That does NOT appear to be what he claimed. What he wrote was: "The board makes the decision who is CEO not me and if you recall our stock was at ~70 cents a share and $70M market cap in May 2017...2 years ago." mnkd.proboards.com/post/182013That is true. In fact, it traded below 0.70 for a time on May 5, 2017 (and also prior to that). |
|
|
|
Post by mnkdfann on Jul 5, 2019 11:44:34 GMT -5
You would have to ask MC specifically what he meant when he said two. He might have been talking about the first two. Or the two largest. Or perhaps all scripts go through two centers. Or maybe it was just a typo. IDK. I guess the point is, MC was not impressed with the VDEX script numbers, especially considering many of them are apparently free scripts. MC also claimed the share price was .70 cent range when he took over as CEO. And if you look at the historical prices, you'll see that it was about 70 cents when MC was presumably approached and agreed to be CEO. After which the price mysteriously started rising significantly over a couple of weeks (my guess it had something to do with some knowing or strongly suspecting that a new CEO was being installed). So, yes, it wasn't 70 cents when he publicly took over but it very possibly and likely was when he agreed to do so. |
|
|
|
Post by mnkdfann on Jul 5, 2019 11:33:38 GMT -5
I thought they have six centers? You would have to ask MC specifically what he meant when he said two. He might have been talking about the first two. Or the two largest. Or perhaps all scripts go through two centers. Or maybe it was just a typo. IDK. I guess the point is, MC was not impressed with the VDEX script numbers, especially considering many of them are apparently free scripts. |
|
|
|
Post by mnkdfann on Jul 5, 2019 11:23:12 GMT -5
Yes, so we give them a shot on a small scale and allow VDEX to purchase at a discount. Didn't MC say that VDEX was already getting about half the scripts for free? How much more of a discount do they need? mnkd.proboards.com/post/182013"VDEX has been claiming for 4 years they have a successful model and solved all the problems, but after 4 years we see <25 scripts a month out of their two centers. If they solved our fundamental challenges they would be doing better and half their scripts wouldn’t be free (ie samples, vouchers etc ultimately costing shareholders money)." |
|
|
|
Post by mnkdfann on Jul 5, 2019 10:39:22 GMT -5
I hope they update the main landing page, and change that HTM to HFM. www.mannkindindependence.com/Unless they really are against Hypertext Markup.  |
|
|
|
Post by mnkdfann on Jul 5, 2019 8:54:31 GMT -5
Perhaps VDEX hasn't shown you the proof, but if they convinced a group of investors with deep pockets, then there is probably something there. Mike / MNKD is being obtuse and I see no logical reason for closing their door and not even meeting with VDEX. What do they have to lose?
I'm not saying they need to take the offer as is, but should be open to some sort of negotiations, contingencies, etc.
I thought it was mentioned somewhere that there was already an initial meeting and MC had turned them down..... I'm not sure about there being a meeting recently, but MC did post that the Board had read Bill's letter and, well, read for yourself: mnkd.proboards.com/post/182013"I realized they are off in left field somewhere and didn’t respond to his updated letter until yesterday bc people didn’t believe the board was aware and wanted to let Bill know the board has read his 7 page letter, but it lacked any financial upfront money that would benefit our shareholders or give it merit for consideration. You all can read the same thing he sent us ...I don’t see any financial terms offered for shareholders giving up rights not to mention all the legal/pricing risks that come with such a proposal." Another post of MC's is interesting to reread, insomuch as it explains the difference between what Vdex asked for and what the other distributorship deals have granted: mnkd.proboards.com/post/182034As for how "things are different for Vdex from other deals we signed ... they are with reputable companies who have infrastructure and expertise with pharmaceutical products, packaging and Regualtory infrastructure. India did have up front money and Brazil didn’t at the time bc people were spouting we were going to disappear so they took a bet with us to invest their money and time to get an approval while we turned around the company here in the US hence why we are 1-2 years ahead there than rest of world on i here Arinola expansion. As for austrailia this is a distributor deal where we technically still own the product and can get rights back...the big challenge is pricing for many partners is not knowing pricing until approval bc government decides. VDEX didn’t have any of types types of things set up for consideration." |
|
|
|
Post by mnkdfann on Jul 4, 2019 23:55:42 GMT -5
Leanne - this board is dying I just saw this...it’s looks alive and well to me:-) Just wait till next week. And the week after. I think pretty much everybody is done with we’re waiting in the wings for something to happen ..that’s getting a little long in the tooth. Nobody can vote their shares twice Mannkind knows how many shares you own it’s in your proxy in your brokerage account. That’s how they count the shares if they ask for a vote on something. But you guys knew that. Lol I wasn't aware that Mannkind was conducting an official vote. I thought we were talking about a de facto anonymous unverified web survey that HFM/Vdex was conducting. |
|
Unless Mannkind is assisting behind the scenes and realizes changing the method for preparation in the U.S. would be daunting and plan on moving forward in China with a different process. I can only imagine the IP mote that is around Afrezza, but I also don't know that any of it would ever slow China down.
